MedTrace Logo

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

NCT04171414 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-11-17

Study results available
· View outcomes & findings →

Summary

Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Conditions

Interventions

BIOLOGICAL

CT-P17 SC AI (adalimumab)

Subcutaneous Injection of Adalimumab 40mg once every two weeks

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Celltrion

    lead INDUSTRY

Principal Investigators

  • MinJi Ma · Celltrion, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-09
Primary Completion
2019-11-04
Completion
2020-04-24

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04171414 on ClinicalTrials.gov